Fennec Pharmaceuticals Inc (FENC) - Total Assets
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) holds total assets worth $75.75 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fennec Pharmaceuticals Inc - Total Assets Trend (1999–2025)
This chart illustrates how Fennec Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see Fennec Pharmaceuticals Inc (FENC) market capitalisation for the company's overall valuation and market capitalisation.
Fennec Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Fennec Pharmaceuticals Inc's total assets of $75.75 Million consist of 95.0% current assets and 5.0% non-current assets. Review how much debt does Fennec Pharmaceuticals Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.4% |
| Accounts Receivable | $23.18 Million | 33.1% |
| Inventory | $1.56 Million | 2.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Fennec Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Fennec Pharmaceuticals Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fennec Pharmaceuticals Inc's current assets represent 95.0% of total assets in 2025, an increase from 67.8% in 1999.
- Cash Position: Cash and equivalents constituted 52.4% of total assets in 2025, up from 17.3% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 33.1% of total assets.
Fennec Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Fennec Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN
|
USA | $910.22 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Fennec Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.85 | 4.85 | 12.90 |
| Quick Ratio | 5.66 | 4.59 | 12.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $60.11 Million | $32.38 Million | $23.96 Million |
Fennec Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Fennec Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.29 |
| Latest Market Cap to Assets Ratio | 5.32 |
| Asset Growth Rate (YoY) | 55.9% |
| Total Assets | $70.07 Million |
| Market Capitalization | $372.41 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Fennec Pharmaceuticals Inc's assets at a significant premium (5.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Fennec Pharmaceuticals Inc's assets grew by 55.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Fennec Pharmaceuticals Inc (1999–2025)
The table below shows the annual total assets of Fennec Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $70.07 Million | +55.89% |
| 2024-12-31 | $44.95 Million | +67.31% |
| 2023-12-31 | $26.86 Million | -0.28% |
| 2022-12-31 | $26.94 Million | +20.19% |
| 2021-12-31 | $22.41 Million | -28.66% |
| 2020-12-31 | $31.42 Million | +122.09% |
| 2019-12-31 | $14.15 Million | -38.36% |
| 2018-12-31 | $22.95 Million | -19.19% |
| 2017-12-31 | $28.40 Million | +615.03% |
| 2016-12-31 | $3.97 Million | +289.79% |
| 2015-12-31 | $1.02 Million | -57.04% |
| 2014-12-31 | $2.37 Million | +35.39% |
| 2013-12-31 | $1.75 Million | -25.92% |
| 2012-12-31 | $2.37 Million | -55.80% |
| 2011-12-31 | $5.35 Million | -10.71% |
| 2010-12-31 | $5.99 Million | +619.45% |
| 2009-12-31 | $833.00K | -86.25% |
| 2008-12-31 | $6.06 Million | -64.79% |
| 2007-12-31 | $17.21 Million | +3.77% |
| 2006-12-31 | $16.58 Million | -41.70% |
| 2005-12-31 | $28.45 Million | -31.84% |
| 2003-12-31 | $41.73 Million | +62.65% |
| 2002-12-31 | $25.66 Million | +276.42% |
| 2001-12-31 | $6.82 Million | -34.80% |
| 2000-12-31 | $10.46 Million | +1525.51% |
| 1999-12-31 | $643.19K | -- |
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has co… Read more